Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy

Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Samit, Lesniak, Wojciech G., Nimmagadda, Sridhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676497/
https://www.ncbi.nlm.nih.gov/pubmed/28707500
http://dx.doi.org/10.1177/1536012117718459
_version_ 1783277078356951040
author Chatterjee, Samit
Lesniak, Wojciech G.
Nimmagadda, Sridhar
author_facet Chatterjee, Samit
Lesniak, Wojciech G.
Nimmagadda, Sridhar
author_sort Chatterjee, Samit
collection PubMed
description Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in, we provide an overview of our efforts to develop clinically translatable PD-L1-specific imaging agents for quantitative and real-time assessment of PD-L1 expression in tumor microenvironment.
format Online
Article
Text
id pubmed-5676497
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-56764972017-11-21 Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy Chatterjee, Samit Lesniak, Wojciech G. Nimmagadda, Sridhar Mol Imaging Commentary Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in, we provide an overview of our efforts to develop clinically translatable PD-L1-specific imaging agents for quantitative and real-time assessment of PD-L1 expression in tumor microenvironment. SAGE Publications 2017-07-14 /pmc/articles/PMC5676497/ /pubmed/28707500 http://dx.doi.org/10.1177/1536012117718459 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Commentary
Chatterjee, Samit
Lesniak, Wojciech G.
Nimmagadda, Sridhar
Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
title Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
title_full Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
title_fullStr Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
title_full_unstemmed Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
title_short Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
title_sort noninvasive imaging of immune checkpoint ligand pd-l1 in tumors and metastases for guiding immunotherapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676497/
https://www.ncbi.nlm.nih.gov/pubmed/28707500
http://dx.doi.org/10.1177/1536012117718459
work_keys_str_mv AT chatterjeesamit noninvasiveimagingofimmunecheckpointligandpdl1intumorsandmetastasesforguidingimmunotherapy
AT lesniakwojciechg noninvasiveimagingofimmunecheckpointligandpdl1intumorsandmetastasesforguidingimmunotherapy
AT nimmagaddasridhar noninvasiveimagingofimmunecheckpointligandpdl1intumorsandmetastasesforguidingimmunotherapy

Ejemplares similares